RSV: Synagis (palivizumab) use highly controlEd by insurance companies due to the expense of about $2000 per month. It must be given every 30 days through out the winter to be effective. Criteria for its use are prematurity with prolonged oxygen use and congenital heart disease. I would recommend you work with your pediatrician and submit an application and see if you can qualify.
Answered 12/26/2014
3.4k views
4 doctors weighed in across 2 answers
A doctor has provided 1 answer
5 doctors weighed in across 3 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question